iRNA agents targeting VEGF

Details iRNA agents targeting VEGF iRNA agents targeting VEGF

2011-05-24

2011-05-24

Vivlemore, Tracy (Department: 1635)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C536S024500

Reexamination Certificate

active

07947659

ABSTRACT:
The features of the present invention relate to compounds, compositions and methods useful for modulating the expression of vascular endothelial growth factor (VEGF), such as by the mechanism of RNA interference (RNAi). The compounds and compositions include iRNA agents that can be unmodified or chemically-modified.

REFERENCES:
patent: 4426330 (1984-01-01), Sears
patent: 4534899 (1985-08-01), Sears
patent: 4837028 (1989-06-01), Allen
patent: 4868116 (1989-09-01), Morgan et al.
patent: 4980286 (1990-12-01), Morgan et al.
patent: 5013556 (1991-05-01), Woodle et al.
patent: 5139941 (1992-08-01), Muzyczka et al.
patent: 5213804 (1993-05-01), Martin et al.
patent: 5225212 (1993-07-01), Martin et al.
patent: 5252479 (1993-10-01), Srivastava
patent: 5264221 (1993-11-01), Tagawa et al.
patent: 5328470 (1994-07-01), Nabel et al.
patent: 5334711 (1994-08-01), Sproat et al.
patent: 5356633 (1994-10-01), Woodle et al.
patent: 5540935 (1996-07-01), Miyazaki et al.
patent: 5543152 (1996-08-01), Webb et al.
patent: 5556948 (1996-09-01), Tagawa et al.
patent: 5595760 (1997-01-01), Cherif-Cheikh
patent: 5627053 (1997-05-01), Usman et al.
patent: 5665710 (1997-09-01), Rahman et al.
patent: 5672659 (1997-09-01), Shalaby et al.
patent: 5705188 (1998-01-01), Junichi et al.
patent: 5716824 (1998-02-01), Beigelman et al.
patent: 5854038 (1998-12-01), Sullenger et al.
patent: 5902880 (1999-05-01), Thompson et al.
patent: 6054299 (2000-04-01), Conrad
patent: 6146886 (2000-11-01), Thompson
patent: 6150092 (2000-11-01), Uchida et al.
patent: 6395713 (2002-05-01), Beigelman et al.
patent: 2003/0203844 (2003-10-01), Delfani et al.
patent: 2004/0018176 (2004-01-01), Tolentino et al.
patent: 2004/0180847 (2004-09-01), Dobie et al.
patent: 2004/0209832 (2004-10-01), McSwiggen et al.
patent: 2005/0255487 (2005-11-01), Khvorova et al.
patent: 2007/0031844 (2007-02-01), Khvorova et al.
patent: 10100586 (2002-04-01), None
patent: WO 89/02468 (1989-03-01), None
patent: WO 89/05345 (1989-06-01), None
patent: WO 89/07136 (1989-08-01), None
patent: WO 92/07065 (1992-04-01), None
patent: WO 92/07573 (1992-05-01), None
patent: WO 93/15187 (1993-08-01), None
patent: WO 93/23569 (1993-11-01), None
patent: WO 93/24641 (1993-12-01), None
patent: WO 94/02595 (1994-02-01), None
patent: WO 94/13788 (1994-06-01), None
patent: WO 96/10390 (1996-04-01), None
patent: WO 96/10391 (1996-04-01), None
patent: WO 96/10392 (1996-04-01), None
patent: WO 96/40062 (1996-12-01), None
patent: WO 97/26270 (1997-07-01), None
patent: WO 98/13526 (1998-04-01), None
patent: WO 99/61631 (1999-02-01), None
patent: WO 99/32619 (1999-07-01), None
patent: WO 99/53050 (1999-10-01), None
patent: WO 00/22113 (2000-04-01), None
patent: WO 00/22114 (2000-04-01), None
patent: WO 00/44895 (2000-08-01), None
patent: WO 00/53722 (2000-09-01), None
patent: WO 03/070910 (2003-08-01), None
patent: WO 03/070917 (2003-08-01), None
patent: WO 2004/001193 (2003-12-01), None
patent: WO 2004/007070 (2004-01-01), None
patent: WO 2004/011822 (2004-02-01), None
patent: WO 2004/011829 (2004-02-01), None
patent: WO 2004/064737 (2004-08-01), None
patent: WO 2004/080406 (2004-09-01), None
patent: WO 2004/094345 (2004-11-01), None
patent: WO 2004/094595 (2004-11-01), None
patent: WO 2004099410 (2004-11-01), None
patent: WO 2005/014782 (2005-02-01), None
Vickers et al. (2003) J. Biol. Chem. 278:7108-7118.
Elbashir et al. (2001) Nature 411:494-498.
Bass (2001) Nature 411:428-9.
Fattal et al. (2006) Advanced Drug Delivery Reviews 58:1203-1223.
Holen et al. (2002) Nucleic Acids Res. 30:1757-1766.
Beigelman et al., “Chemical Modification of Hammerhead Ribozymes”J. Biol. Chem270:25702-25708 (1995).
Bernstein et al., “Role for a bidentate ribonuclease in the initiation step of RNA interference”Nature409:363-366 (2001).
Burgin et al., “Chemically Modified Hammerhead Ribozymes with Improved Catalytic Rates”Biochemistry35:14090-14097 (1996).
Burlina et al., “Chemical Engineering of RNase Resistant and Catalytically Active Hammerhead Ribozymes”Bioorg. Med. Chem. 5(11):1999-2010 (1997).
Chen et al., “Multitarget-ribozyme directed to cleave at up to nine highly conserved HIV-1 env RNA regions inhibits HIV-1 replication-potential effectiveness against most presently sequenced HIV-1 isolates”Nucleic Acids Res. 20(17):4581-4589 (1992).
Chowrira et al., “In Vitro and In Vivo Comparison of Hammerhead, Hairpin, and Hepatitis Delta Virus Self-processing Ribozyme Cassettes”J. Biol. Chem. 269(41):25856-25864 (1994).
Couture et al., “Anti-gene therapy: the use of ribozymes to inhibit gene function”Trends in Genetics12(12):510-515 (1996).
Dropulic et al., “Functional Characterization of a U5 Ribozyme: Intracellular Suppression of Human Immunodeficiency Virus Type 1 Expression”J. Virol. 66(3):1432-1441 (1992).
Dunn et al., “ARPE-19, A Human Retinal Pigment Epithelial Cell Line with Differentiated Properties”Exp. Eye Res. 62:155-169 (1996).
Earnshaw and Gait, “Modified Oligoribonucleotides as Site-Specific Probes of RNA Structure and Function”Biopolymers(Nucleic Acid Sciences) 48:39-55 (1998).
Elbashir et al., “RNA interference is mediated by 21- and 22-nucleotide RNAs”Genes and Dev. 15:188-200 (2001).
Filleur et al., “SiRNA-mediated Inhibition of Vascular- Endothelial Growth Factor Severely Limits Tumor Resistance to Antiangiogenic Thrombospondin-1 and Slows Tumor Vascularization and Growth”Cancer Res. 63:3919-3922 (2003).
Fire et al., “Potent specific genetic interference by double-stranded RNA inCaenorhabditis elegans” Nature391:806-811 (1998).
Genbank Accession No. AF214570, “Homo sapiensvascular endothelial growth factor isoform 121 precursor, mRNA, complete cds,” Dec. 23, 1999.
Good et al., “Expression of small, therapeutic RNAs in human cell nuclei”Gene Therapy4:45-54 (1997).
Izant and Weintraub, “Constitutive and Conditional Suppression of Exogenous and Endogenous Genes by Anti-Sense RNA”Science229:345-352 (1985).
Karpeisky et al., “Highly Efficient Synthesis of 2′-O-Amino Nucleosides and Their Incorporation in Hammerhead Ribozymes”Tetrahedron Lett. 39:1131-1134 (1998).
Kashani-Sabet et al., “Reversal of the Malignant Phenotype by an Anti-rasRibozyme”Antisense Res. Dev. 2:3-15 (1992).
Kawaski et al., “Uniformly Modified 2′-Deoxy-2′-fluoro Phosphorothioate Oligonucleotides as Nuclease-Resistant Antisense Compounds with High Affinity and Specificity for RNA Targets”J. Med. Chem. 36:831-841 (1993).
Kumar et al., “Express Protocol for Functionalization of Polymer Supports for Oligonucleotide Synthesis”Nucleosides&Nucleotides15(4):879-888 (1996).
McGarry and Lindquist, “Inhibition of heat shock protein synthesis by heat-inducible antisense RNA”Proc. Natl. Acad. Sci. USA83:399-403 (1986).
Nykänen et al., “ATP requirements and small interfering RNA structure in the RNA interference pathway”Cell107:309-321 (2001).
Ohkawa et al., “Activities of HIV-RNA targeted ribozymes transcribed from a ‘shot-gun’ type ribozyme-trimming plasmid”Nucleic Acids Symp. Ser. 27:15-16 (1992).
Ojwang et al., “Inhibition of human immunodeficiency virus type 1 expression by a hairpin ribozyme”Proc. Natl. Acad. Sci. USA89:10802-10806 (1992).
Perrault et al., “Mixed deoxyribo- and ribo- oligonucleotides with catalytic activity”Nature344:565-567 (1990).
Pieken et al., “Kinetic Characterization of Ribonuclease-Resistant 2 prime—Modified Hammerhead Ribozymes”Science253:314-317 (1991).
Prakash et al., “Synthesis of 2′-O-[2-[(N,N-Dimethylamino)oxy]ethyl] Modified Nucleosides and Oligonucleotides”J. Org. Chem. 167:357-369 (2002).
Reich et al., “Small interfering RNA (siRNA) targetingVEGFeffectively inhibits ocular neovascularization”Mol. Vis. 9:210-216 (2003).
Sarver et al., “Ribozy

Affiliated with

Also associated with

Rating

iRNA agents targeting VEGF does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with iRNA agents targeting VEGF, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and iRNA agents targeting VEGF will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2634703